Format

Send to

Choose Destination
Eur J Med Chem. 2018 Mar 25;148:397-409. doi: 10.1016/j.ejmech.2018.02.049. Epub 2018 Feb 17.

Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.

Author information

1
Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, 305-764, Republic of Korea.
2
LegoChem Biosciences, Inc., 8-26 Munoyeongseo-ro, Daedeok-gu, Daejeon, 34302, Republic of Korea.
3
LegoChem Biosciences, Inc., 8-26 Munoyeongseo-ro, Daedeok-gu, Daejeon, 34302, Republic of Korea. Electronic address: dlee@legochembio.com.
4
Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, 305-764, Republic of Korea. Electronic address: nskang@cnu.ac.kr.

Abstract

Autotaxin (ATX) is a potential target for the treatment of various cancers. A new series of ATX inhibitors was rationally designed and synthesized based on our previous study. Biological evaluation and structure-activity relationship (SAR) of this series are discussed. Among fourteen synthesized derivatives, six compounds (2, 3, 4, 12, 13 and 14) exhibited enhanced ATX inhibitory activities with IC50 values in the low nanomolar range. Molecular interactions of all the synthesized compounds within the active site of ATX were studied through molecular docking studies. Herein, we describe our lead optimization efforts that resulted in the identification of a potent ATX inhibitor (compound 4 with IC50 = 1.23 nM, FS-3 and 2.18 nM, bis-pNPP). Furthermore, pharmacokinetic properties of this most promising compound are profiled.

KEYWORDS:

ATX inhibitors; Autotaxin; Cancer; Molecular docking; Pharmacokinetics

PMID:
29477073
DOI:
10.1016/j.ejmech.2018.02.049
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center